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Background: High levels of distress and need for self-care information by patients commencing chemotherapy
suggest that current prechemotherapy education is suboptimal. We conducted a randomised, controlled trial of
a prechemotherapy education intervention (ChemoEd) to assess impact on patient distress, treatment-related
concerns, and the prevalence and severity of and bother caused by six chemotherapy side-effects.
Patients and methods: One hundred and ninety-two breast, gastrointestinal, and haematologic cancer patients
were recruited before the trial closing prematurely (original target 352). ChemoEd patients received a DVD, question-
prompt list, self-care information, an education consultation ‡24 h before first treatment (intervention 1),
telephone follow-up 48 h after first treatment (intervention 2), and a face-to-face review immediately before second
treatment (intervention 3). Patient outcomes were measured at baseline (T1: pre-education) and immediately
preceding treatment cycles 1 (T2) and 3 (T3).
Results: ChemoEd did not significantly reduce patient distress. However, a significant decrease in sensory/
psychological (P = 0.027) and procedural (P = 0.03) concerns, as well as prevalence and severity of and bother due to
vomiting (all P = 0.001), were observed at T3. In addition, subgroup analysis of patients with elevated distress at T1
indicated a significant decrease (P = 0.035) at T2 but not at T3 (P = 0.055) in ChemoEd patients.
Conclusions: ChemoEd holds promise to improve patient treatment-related concerns and some physical/
psychological outcomes; however, further research is required on more diverse patient populations to ensure
generalisability.
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introduction
Patients scheduled to receive cancer chemotherapy often suffer
pretreatment psychological distress [1–3]. Many report
common physical and psychosocial sequelae (e.g. nausea,
fatigue, hair loss, treatment-related worry) cause a great deal of
concern [4–6] and rates of psychiatric and psychosocial
morbidity are typically high [2, 7, 8]. Patients require detailed
preparatory information to cope with chemotherapy treatment
and the self-management [9] of often complex treatment-
related side-effects in the community. However, current
research indicates that patients report high levels of unmet need
in relation to the provision of self-care information and the
things they can do to keep well [10, 11].
The high incidence of patient psychological distress and need
for self-care information suggest that current prechemotherapy
preparation is suboptimal; however, few studies have addressed
this area. An early study showed that information about side-
effects improved patient self-care activity [12]; however, this
was a study of only 60 participants, involving relatively simple
chemotherapy regimens. Audiovisual resources within
chemotherapy education have recently been shown to reduce
patient anxiety [13] and promote higher recall of symptom
information [14]. A second trial of 70 participants showed
a nonstatistically significant increase in self-care behaviours and
reduction in reported symptoms following changes to
prechemotherapy education; however, interpretation is difficult
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given that this study was likely underpowered [15]. All other
studies have only focused on improvements in specific side-
effects such as oral mucositis [16, 17] or fatigue, as a result of
changes to patient education [18]. Thus, the overall evidence
base for preparation of patients for chemotherapy is limited.
Literature regarding the preparation of patients for
potentially threatening medical procedures [9, 19, 20], as well
as health education research [21], provides a robust framework
that can be adapted to the prechemotherapy setting. Evidence
from other patient settings, predominantly surgery, suggests
that the provision of adequate and timely sensory,
psychological, and procedural information has broad benefits,
including reduced psychological distress [9, 20, 22]. The trial
reported here systematically applied this and other relevant
literature to the development of a nurse-led education
intervention (ChemoEd) for patients commencing their first
ever chemotherapy treatment. Evaluation of ChemoEd focussed
on common chemotherapy-related concerns including
psychological distress, treatment-related information and
support needs, and symptom burden. Assessment of symptom
burden included measurement of both severity and bother
caused by six commonly experienced chemotherapy symptoms
(nausea, vomiting, infection, hair loss, mouth/throat problems,
and fatigue). Symptoms were chosen following a systematic
review of the literature [23], which indicated that they were
commonly experienced as a result of chemotherapy, were
perceived as distressing, and/or were related to patient safety;
and that evidence-based self-care strategies were available for
amelioration of the symptom itself or the distress caused by the
symptom.
Assessment of the success of the ChemoEd intervention was
based on two research questions: (i) what was the impact of
changes to both the timing and the structure of
prechemotherapy education on psychological distress on the
first day of treatment and (ii) what was the impact of the total
ChemoEd package (including subsequent patient follow-up
and coaching) on psychological distress, symptoms, and
treatment-related concerns over time? The primary hypothesis
of this study was that patients randomised to the ChemoEd
intervention would report decreased psychological distress at
the time of first treatment (Q1) and over time (Q2) when
compared with patients in the usual care (control) group.
Additionally, it was hypothesised that the total ChemoEd
intervention would result in decreased cancer treatment-related
information and support needs and would lead to decreased
burden (severity and bother) caused by six common
chemotherapy symptoms (nausea, vomiting, infection,
mucositis, fatigue, and hair loss).
patients and methods
The study was conducted at the Peter MacCallum Cancer Centre (Peter
Mac), a specialist cancer hospital in Melbourne, Australia. The Human
Research Ethics Committee at Peter Mac approved the study. The study was
registered with the Australian New Zealand Clinical Trials Registry. A
consecutive sample of patients attending the outpatient clinics at Peter Mac
between September 2005 and December 2007 were screened for eligibility.
Eligibility criteria included the following: (i) diagnosis of nonmetastatic
breast, gastrointestinal, or haematologic cancer (Hodgkin’s lymphoma,
non-Hodgkin’s lymphoma, and chronic lymphocytic leukaemia); (ii)
scheduled to receive first ever course of chemotherapy; (iii) planned to
receive at least three cycles of chemotherapy given with curative intent; (iv)
aged >18 years; and (v) able to speak, read, and write in English. Exclusion
criteria included the following: Eastern Cooperative Oncology Group
(ECOG) performance status score more than two and severe cognitive/
emotional issues as determined by the patient’s treating oncologist. Breast,
gastrointestinal, and haematologic cancers were chosen for inclusion in this
study due to their high prevalence in the cancer population and to assess
the intervention in both solid and nonsolid tumour groups.
study design
A parallel group-prospective randomised, controlled trial was undertaken
with patients randomised to receive ChemoEd or routine care/
prechemotherapy education. Baseline data (T1) were collected in the week
preceding patients’ first ever chemotherapy. Randomisation was completed
via random number generator with stratification for cancer type and
treatment toxicity (high versus low, predetermined by clinical investigators
based on the likelihood of patients developing febrile neutropenia during
treatment). Individual patients were randomised immediately following
completion of baseline measures via sequentially numbered opaque
envelopes concealing group allocation. Blinding of participants to group
allocation was not possible given the nature of the intervention; however,
research assistants not involved in the intervention delivery carried out all
patient data collection.
intervention framework (ChemoEd). ChemoEd was informed by evidence
relevant to four key domains: preparing patients for potentially threatening
procedures [9, 19, 20], tailoring to the specific needs of individuals [21, 24],
emphasising evidence-based self-care [23], and psychosocial support [20].
It consisted of four key resources including a chemotherapy educational
DVD [25, 26], a DVD question-prompt list to facilitate education tailoring,
one-page drug information sheets that contained sensory and procedural
information, and one-page evidence-based self-care brochures on 16
different topics outlining strategies to lessen common chemotherapy side-
effects. These resources were utilised within a structured delivery
framework (Figure 1; supplemental Appendix S1, available at Annals of
Oncology online). ChemoEd sessions focused on eliciting and responding to
patient-identified concerns/fears, delivery of tailored evidence-based
messages about chemotherapy side-effects, and discussion and coaching of
relevant self-care strategies to manage toxic effects/side-effects and
psychological distress. All ChemoEd prechemotherapy education sessions
(i.e. intervention 1) were scheduled between 1 and 7 days before first
treatment, in a private room away from the treatment area.
routine care/prechemotherapy education. Routine care consisted of a nurse-
led education session covering common side-effects of chemotherapy
provided on the first day of treatment either in the treatment chair of
a shared ward or in the communal waiting area. The educational DVD used
in ChemoEd was freely available in the chemotherapy day unit; therefore,
use of this resource was monitored. No follow-up patient contacts were
scheduled as part of routine care.
outcome measurement
Written informed consent was obtained at T1 before randomisation and
before any study procedures. Patients completed self-administered
questionnaires in outpatient clinics at T1, T2, and T3.
clinical data. Information on ECOG performance status, cancer type, stage,
and treatment regimen was collected from the patient record.
demographic data. Age and gender were collected from the patient record.
Other items were collected at T1 in the patient-completed questionnaire
(marital status, current employment, education, and country of birth).
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psychological distress. Psychological distress was assessed with the Hospital
Anxiety and Depression Scale (HADS) [27, 28] at T1, T2, and T3. The
HADS is a self-report 14-item measure with two subscales (anxiety and
depression), which may be scored by scale or as a total score representing
overall distress. The HADS total score provides a robust indicator of
psychological morbidity in cancer patients [29–32] and exhibits sound
psychometric properties [33–36] including responsiveness to change [13].
A total score of 15 is considered a good predictor of general psychological
morbidity/distress [32, 37–39].
cancer treatment-related information and support needs. These were
measured with the Cancer Treatment Scale (CaTS) at T1 and T3. This 25-
item self-report measure asked participants to reflect on what hospital staff
could have done to help them cope better in the time leading up to
treatment. Participants then indicated the extent to which they agree or
disagree with items using a five-point Likert scale (1 strongly disagree to 5
strongly agree). CaTS is composed of two subscales: a 14-item sensory–
psychological concerns (SPC) subscale and an 11-item procedural concerns
(PC) subscale. Both subscales demonstrate high internal consistency (a >
0.9) and good divergent validity (r < 0.3) based on correlations with HADS
anxiety and total scores as well as responsiveness to change (under editorial
review).
common chemotherapy-related symptoms. These were assessed with the
Chemotherapy Symptom Assessment Scale (C-SAS) [40] at T1 and T3. This
is a 24-item self-report measure with demonstrated validity, reliability, and
responsiveness to change in cancer patients [40]. Respondents indicate if
they have experienced any of a list of symptoms since their last
chemotherapy treatment (0 = no and 1 = yes). If a symptom is marked as
present, they then rate the severity of that symptom (1 = mild to 3 = severe)
and the extent of bother caused by it (0 = not at all to 3 = very much).
intervention fidelity
Nurses who educated participants with ChemoEd were recruited from the
chemotherapy day unit and trained in delivery of the intervention content
and in communication skills (responding and eliciting to emotional cues;
Provision of pre-chemotherapy
education resources to patient
(DVD, Question Prompt List)
Intervention 1
(pre-chemotherapy education)
Face-to-face education session
with in a private room accompanied by
provision of additional 
patient resources
(Drug Information Sheets, Self-
Care Brochures, chemotherapy 
information booklet) and tour of the 
Chemotherapy Day Ward.
Patient commences
Chemotherapy treatment 
Intervention 2 
(phone call)
Assesses the patient experience of first 
treatment, identifies any issues, 
and provides patient coaching in use of
self-care strategies
(provision of additional information
resources as required)
7 days approx
1-7 days approx
2-5 days approx
Intervention 3
(face-to-face)
Conducted immediately prior to 
commencement of second treatment
(cycle 2) to review patient issues and 
provide additional coaching of 
self-care strategies
(provision of additional information
resources as required)
2-3 weeks approx
eraClausUdEomehC
Patient pre-chemotherapy education*
Face-to-face education session on
the first day of chemotherapy
treatment occurs in a public
space (eg treatment chair or waiting
room) with provision of limited 
resources (eg chemotherapy information
booklet; generic drug sheets with no 
sensory or procedural information).
* Usual Care nurse educators have not received 
communication skills training
DAY 1
CYCLE 1
DAY 1
CYCLE 2
Figure 1. Structure and timing of usual care patient prechemotherapy education versus the ChemoEd intervention.
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supplemental Appendix S1, available at Annals of Oncology online).
Intervention nurses were not permitted to provide education to
participants in the routine care group and were discouraged from
talking about the intervention with other nurses.
Prechemotherapy education sessions for all study participants were audio
taped and content analysis carried out to assess intervention fidelity,
consistency over time, and diffusion into routine care. Checklists were
completed for each component of the ChemoEd intervention to assess
completeness.
study end points
The primary end point of this study was psychological distress at T2 and T3
as measured by the HADS. Secondary end points included treatment-
related information and support needs (as measured by the CaTS) and
decreased symptom burden (severity and bother) due to six common
chemotherapy symptoms as measured by the C-SAS (nausea, vomiting,
infection, mucositis, fatigue, and hair loss). It was hypothesised that
patients receiving the ChemoEd intervention would have significantly lower
psychological distress at T2 and T3, treatment-related information/support
needs, and symptom burden when compared with patients in the control
group.
statistical power and analyses
Initial sample size calculations were based on the detection of a small effect
[41] on the primary outcome measure of psychological distress as
measured by the HADS. To detect an effect size of 0.30 standard deviations
(two-sided 5% significance level; 80% power), 352 participants were
required.
statistical analysis
All data were analysed with SPSS version 17.0 (SPSS, Chicago, IL).
Independent samples t-tests for continuous variables, Mann–Whitney U
tests for ordinal variables, and Pearson’s v2 or Fisher’s exact test for
nominal variables were used to compare demographic, clinical, and
psychosocial characteristics of the control and intervention arms at
baseline. Questionnaire compliance (missing items and forms) was also
assessed. Analyses were carried out using the ‘all-available’ approach to
maximise available pairwise information. With this approach, the number
of observations used in calculations varies for each analysis [42].
The impact of the first intervention session of ChemoEd on psychological
distress on the first day of treatment was assessed using analysis of
covariance (ANCOVA). Additionally, the impact of the total ChemoEd
intervention on psychological distress and cancer treatment-related
concerns was evaluated using ANCOVA [43]. Separate ANCOVAs were run
for each outcome variable (HADS total scores and CaTS subscale scores
used as dependent variables) at each follow-up assessment with study group
as the between-subjects factor and relevant baseline score as the covariate.
Initially, age, marital status, sex, functional impairment, and symptom
prevalence were included as covariates; however, these made little difference
to interpretation, so were excluded. In these analyses, alpha was set at 0.05
(two-tailed).
Odds ratios and Pearson’s v2 were used to assess the relationship between
the prevalence of common chemotherapy side-effects and study group at T1
and T3. Mann–Whitney U tests were used to assess the impact of ChemoEd
on the severity of and bother caused by common chemotherapy side-effects.
A more stringent alpha of 0.01 (two-tailed) was employed to correct for
multiple testing.
Exploratory subgroup analyses were undertaken in those patients with
elevated psychological distress (‡15 on HADS) [30, 37, 39] at T1.
Independent samples t-tests were used to identify group differences in mean
distress levels at baseline. Two separate ANCOVAs were subsequently run
(for each follow-up assessment)—with study group as the between-subjects
factor, T2 and T3 HADS total scale scores used as dependent variables, and
baseline/T1 HADS score as the dependent measure.
results
trial profile
Overall, 2370 outpatients were screened for eligibility (Figure 2)
and 309 were eligible. A total of 247 patients (80%) were
approached and 192 (82%) patients consented and completed
baseline measures (T1) between September 2005 and December
2007.
There were no significant differences in patient
characteristics between groups (Table 1).
prechemotherapy education content and
intervention fidelity
All patients randomised to ChemoEd received the educational
DVD after completing the baseline questionnaire and 90% (n =
89) watched it. In contrast, only 9% (n = 8) of control
participants reported watching the DVD. The average time for
the completion of prechemotherapy education (intervention 1)
was 40.36 min (615.03) and for routine care education 24.28
min (610.43). Average time taken to complete interventions 2
and 3 were 9.84 (64.52) and 15.92 (67.24) min, respectively.
Fidelity assessment of the recorded intervention sessions will
be reported elsewhere but completeness of all intervention
elements ranged from 72% to 84%, with no significant
degradation of intervention nurse performance over the
duration of the study. There was no diffusion into usual care
identified during assessment of the audiotapes. Almost all
(94%, n = 92) patients completing T3 measures received all
three intervention components.
questionnaire compliance
Compliance with questionnaires was high (‡94%) at all
planned assessments (supplemental Appendix S2, available at
Annals of Oncology online) with minimal missing items for all
scales and subscales (<1.0%).
psychological distress
At T1, mean HADS scores did not differ significantly between
groups, t(189) = 0.72, P = 0.47. At T2 (after delivery of the first
intervention session) and T3, psychological distress scores
improved more on average in the treatment than in the control
group; however, these differences were not significant (Table 2).
cancer treatment-related concerns
At T1, mean SPC scores did not differ significantly between
groups, t(190) = 20.59, P = 0.56, whereas mean PC scores were
significantly higher in the ChemoEd group, t(190) = 22.3, P =
0.022. Adjusting for differences in T1 scores, subscale scores at
T3 indicated a significant improvement in the ChemoEd group
on both the SPC (P = 0.027) and the PC (P = 0.03) subscales
(Table 3).
prevalence and severity of and bother caused by
six common chemotherapy side-effects
At T1, there were no significant between-group
differences in terms of prevalence, severity, and bother
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related to individual side-effects. While there were
few significant differences at T3, prevalence of vomiting as well
as the severity of and bother caused by vomiting were
reduced in patients receiving ChemoEd (all P = 0.001)
(Table 4).
exploratory subgroup analysis—distress
Prerandomisation, a total of 54 patients [control, n = 26 (28%);
intervention, n = 28 (29%)] reported elevated distress
levels (Table 5). At T1, mean HADS scores for patients with
elevated distress were significantly higher in the control group,
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Figure 2. CONSORT diagram of the ChemoEd randomised controlled trial. HADS, Hospital Anxiety and Depression Scale; Cancer Treatment Scale; C-
SAS, Chemotherapy Symptom Assessment Scale.
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t(52) = 2.2, P = 0.035. After adjusting for T1 scores, a significant
decrease in psychological distress at T2 (P = 0.035) was
observed in ChemoEd participants; however, this between-
group difference was not maintained at T3 (P = 0.055).
sample size and statistical power
Due to scheduled changes in patient prechemotherapy
education as part of usual care (changes to patient education
materials and timing of education), in combination with
slower-than-anticipated recruitment rates, the trial was
closed prematurely to avoid potential confounding of study
outcomes. This meant that with a final sample of 192
patients, post hoc power analysis (two-sided 5% significance
level; sample size group 1 = 98, sample size group 2 = 94) for a
small effect (d = 0.30) indicated a 54% probability that
statistical significance would be indicated on the primary end
point, whereas the corresponding probability for
a moderate effect (d = 0.50) was 93%.
discussion
Patients require preparation before commencing
chemotherapy, which is commonly a very stressful time.
Educating patients before chemotherapy is generally a role of
Table 1. Characteristics of patients in the ChemoEd trial at baseline per treatment group
Control (n = 94) (routine care) Intervention (n = 98) (ChemoEd) P
n % n %
Age, years
<65 77 82 82 84 0.75
>65 17 18 16 16
Mean 53.5 51.4 0.24
SD 13.6 12.0
Sex
Female 66 70 59 60 0.15
Male 28 30 39 40
Marital status
Married/living with partner 69 73 66 67 0.36
Not married/living with partner 25 27 32 33
Employment status
Working 43 46 35 36 0.16
Not working 51 54 63 64
Education
Completed primary/secondary school 41 44 32 33 0.48
Vocational 18 19 23 23
University 32 34 39 40
Not stated 3 3 4 4
Site of cancer
Breast 42 45 41 42 0.69
Lymphoma/leukaemiaa 25 27 27 28 0.88
GIb 27 29 30 31 0.78
Staging of cancer
I 17 18 15 15 0.42
II 25 27 29 30
III 40 43 34 35
IV 12 13 20 20
ECOG performance status
0 63 69 67 69 0.99
1 24 26 26 27
2 4 4 4 4
Chemotherapy program
Chemotherapy only 76 81 78 80 0.83
Chemotherapy and radiotherapy 18 19 20 20
Chemotherapy toxicity
Low 46 49 47 48 0.89
High 48 51 51 52
aControl: chronic lymphocytic leukaemia (CLL), n = 2; Hodgkin’s disease, n = 7; and non-Hodgkin’s lymphoma, n = 16. Intervention: CLL, n = 4; Hodgkin’s
disease, n = 4; and non-Hodgkin’s lymphoma, n = 19.
bControl: upper GI, n = 10; lower GI, n = 17. Intervention: upper GI, n = 8; lower GI, n = 22.
SD, standard deviation; GI, gastrointestinal; ECOG, Eastern Cooperative Oncology Group.
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the specialist cancer nurse. There is little evidence to guide the
structure and delivery of pretreatment education. ChemoEd
was developed using high-level evidence—evidence from
systematic literature reviews regarding (i) preparation of
patients for potentially threatening medical procedures and (ii)
the use of evidence-based self-care messages to ameliorate
chemotherapy treatment-related side-effects [23].
Delivery of the ChemoEd intervention was generally
complete and was consistent across the study time frame, with
no diffusion into routine care. Likewise 94% of the ChemoEd
participants received all three scheduled intervention sessions.
Despite high intervention integrity, the primary hypothesis that
patients receiving ChemoEd would report decreased distress
was not supported. However, several secondary end points were
supported including a reduction in information and support
needs regarding preparation for treatment and a reduction in
the prevalence and severity of and bother caused by vomiting.
Compared with patients in the usual care group, patients with
elevated distress at baseline randomised to ChemoEd reported
a significant decrease in distress at the T2 time point (before
cycle 1). This decrease was not sustained at cycle 3. Overall, our
data suggest that ChemoEd might be best utilised when tailored
to patient baseline (prechemotherapy education) distress.
Patients with low distress may need less intense education,
whereas those with high distress may benefit from more
intensive preparation and follow-up.
An interesting finding of this study was that despite the
availability of the education DVD in routine care, few patients
in the routine care arm watched this. This demonstrates that
structured approaches, such as the use of intervention
checklists, may be useful additions to routine practice to ensure
patients access available support materials. Access to
appropriate information and support materials (such as DVD
and self-care brochures) is likely to help reduce treatment-
related information and support needs.
Although this study suggests that the ChemoEd intervention
is superior to current routine care, the study has several
limitations. First, despite being more than twice as large as any
prior evaluation of a nurse-led prechemotherapy education
program [12, 14], we cannot rule out the possibility that our
findings may have been limited by our sample size and that
a larger sample may have allowed us to detect smaller between-
group differences on our primary outcome variable. However,
analyses for all secondary outcome variables, as well as
subgroup analyses, were sufficiently powered and all observed
differences corresponded with clinically meaningful changes.
Second, the study was undertaken at a single specialist cancer
hospital and studied a limited patient population. Whether this
approach can be applied successfully to people with other
cancer types and those treated at nonspecialist centres requires
further exploration. Likewise, the study did not assess all
chemotherapy types or those patients who had received
previous chemotherapy. It involved few patients receiving
concurrent radiotherapy or with advanced cancer. In addition,
resources were only available in English and therefore those
patients not fluent in English and those likely at increased risk
for adverse outcomes [45, 46] and most likely to benefit from
the intervention were not included in the study. Further studies
are therefore warranted to fully explore the potential benefits of
the ChemoEd intervention across a more diverse cancer
population and to establish whether some groups are more
likely to benefit from these education changes.
A further limitation is that the study had no mechanism for
monitoring patient use of recommended self-care information
in the home environment. There was no way of identifying the
extent to which patients undertook suggested self-care
activities. It is also possible that the HADS, used to measure
psychological distress, was not the ideal instrument to measure
treatment-related distress. The HADS is based on Diagnostic
and Statistical Manual of Mental Disorders-IV criteria for
Table 2. Results of ChemoEd trial for psychological distress (HADS)
Control (routine care),
mean (SD)
Intervention (ChemoEd),
mean (SD)
b (95% CI)a F P Partial g2 Cohen’s d
T1 12.1 (7.0) 11.4 (6.2)
T2 10.9 (6.8) 9.9 (5.8) 0.51 (20.53 to 1.6) 0.94 0.33 0.005 0.28
T3 10.4 (7.0) 9.0 (5.8) 1.1 (20.39 to 2.5) 2.1 0.15 0.011 0.29
aFor each analysis, the regression coefficient b provides an estimate of the difference between the mean change scores of study arms [44].
HADS, Hospital Anxiety and Depression Scale; SD, standard deviation; CI, confidence interval.
Table 3. Results of ChemoEd trial for the Cancer Treatment Scale
Control (routine care),
mean (SD)
Intervention (ChemoEd),
mean (SD)
b (95% CI)a F P Partial g2 Cohen’s d
SPC T1 3.0 (0.98) 3.1 (0.90)
T3 2.3 (0.88) 2.0 (0.82) 0.26 (0.03–0.49) 5.0 0.027 0.027 0.29
PC T1 3.4 (1.1) 3.7 (0.90)
T3 2.5 (0.95) 2.2 (0.95) 0.39 (0.13–0.65) 9.0 0.003 0.048 0.31
aFor each analysis, the regression coefficient b provides an estimate of the difference between the mean change scores of study arms [44].
SPC, sensory–psychological concerns subscale; SD, standard deviation; CI, confidence interval; PC, procedural concerns subscale.
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psychiatric disorder, which may not adequately reflect patient
experience before receiving chemotherapy. Although the
ChemoEd intervention did appear to positively impact on
psychological distress, we suggest that further work be
undertaken to fully elucidate the nature and measurement of
treatment-related distress in the cancer setting and how such
distress changes over the course of treatment.
The shift from inpatient to ambulatory delivery of
chemotherapy places a significant burden on patients and
their carers to assess and manage treatment toxic effects and
side-effects in the home environment. ChemoEd provides
an evidence-based approach to patient education that
impacted positively on sensory and procedural concerns
related to treatment, reduced distress in those who were more
distressed before treatment, and reduced the severity of and
bother related to vomiting. These benefits need to be offset
against the increased time taken to provide this type of
education. It was not possible to assess other benefits that
may have resulted from the intervention such as improved
workflow.
Table 4. Results of the ChemoEd Trial for six common chemotherapy side-effects (C-SAS)
Prevalence Control (routine care) Intervention (ChemoEd) OR (CI) P
Valid data (n) % with
side-effect
Valid data (n) % with
side-effect
Nausea T1 92 23 98 20 0.87 (0.43–1.7) 0.69
T3 89 64 94 63 0.95 (0.52–1.7) 0.86
Vomiting T1 92 5 98 9 1.8 (0.57–5.5) 0.32
T3 87 28 93 9 0.25 (0.10–0.59) 0.001
Infection T1 94 17 98 13 0.75 (0.34–1.6) 0.47
T3 88 27 94 28 1.0 (0.53–2.0) 0.95
Hair loss T1 94 1 98 1 0.96 (0.059–15.6) 0.98
T3 87 76 94 67 0.65 (0.34–1.2) 0.19
Mouth or throat problems T1 93 15 98 10 0.64 (0.27–1.5) 0.31
T3 88 53 94 42 0.62 (0.34–1.1) 0.11
Fatigue T1 94 39 98 51 1.6 (0.91–2.8) 0.11
T3 89 81 94 75 0.69 (0.34–1.4) 0.30
Severity Control (routine care),
Mean rank
Intervention (ChemoEd),
Mean rank
Mann–Whitney U P
Nausea T1 97.3 93.8 4341.5 0.54
T3 94.7 89.5 3945.0 0.48
Vomiting T1 94.2 96.7 4387.0 0.49
T3 99.3 82.3 3278.0 0.001
Infection T1 99.0 94.1 4371.0 0.34
T3 92.4 90.7 4057.0 0.77
Hair loss T1 96.5 96.5 4604.5 0.98
T3 95.5 86.9 3699.0 0.25
Mouth or throat problem T1 99.4 92.8 4245.5 0.17
T3 98.6 84.8 3508.0 0.052
Fatigue T1 90.7 102.0 4064.0 0.11
T3 94.1 90.0 3995.5 0.58
Bother Control (routine care),
Mean rank
Intervention (ChemoEd),
Mean rank
Mann–Whitney U P
Nausea T1 97.8 93.3 4295.0 0.45
T3 93.4 90.7 4061.0 0.72
Vomiting T1 95.7 95.4 4493.0 0.92
T3 98.9 82.6 3313.0 0.001
Infection T1 99.4 93.7 4332.5 0.30
T3 92.8 90.3 4025.5 0.69
Hair loss T1 96.5 96.5 4603.5 0.97
T3 98.4 84.2 3445.5 0.059
Mouth or throat problem T1 99.4 92.8 4240.5 0.18
T3 97.3 86.1 3629.0 0.12
Fatigue T1 92.6 100.3 4236.0 0.28
T3 90.9 93.0 4088.5 0.78
In the case of the C-SAS, some patients did not provide responses to all six items relevant to the six common side-effects.
C-SAS, Chemotherapy Symptom Assessment Scale; OR, odds ratio; CI, confidence interval.
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conclusions
The current ChemoEd program addresses the need for
enhanced patient education and preparation for self-
management in the ambulatory setting and is potentially
suitable as a widespread program to improve patient care.
However, its generalisability across different settings and
diverse patient populations needs further investigation,
alongside consideration of practical aspects such as the cost of
additional nursing time and strategies to increase the impact
of such interventions on patient outcomes.
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